Article
Medicine, General & Internal
P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis
Summary: In this study, patients with relapsed and refractory multiple myeloma received oral mezigdomide in combination with dexamethasone. The combination therapy showed promising efficacy in heavily pretreated patients with multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Jacob P. Laubach, Sascha A. Tuchman, Jacalyn M. Rosenblatt, Constantine S. Mitsiades, Kathleen Colson, Kelly Masone, Diane Warren, Robert A. Redd, Dena Grayson, Paul G. Richardson
Summary: The phase 1b study demonstrated the potential of Pano-RVd treatment for relapsed and refractory multiple myeloma, showing promise in overcoming lenalidomide and/or bortezomib resistance.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Seok Jin Kim, Danbee Kang, Yong Park, Yeung-Chul Mun, Kihyun Kim, Jin Seok Kim, Chang-Ki Min, Juhee Cho
Summary: This study found that depression prior to Rd treatment in MM patients was significantly associated with poor adherence to the treatment. Active interventions to reduce depression should be considered for MM patients prior to Rd treatment to improve treatment adherence.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Joshua Richter, Peggy L. Lin, Viviana Garcia-Horton, Patricia Guyot, Erin Singh, Zheng-Yi Zhou, Mark Sievert, Riley Taiji
Summary: In this study, the efficacy and safety of Isa-Kd was compared with Dara-Rd for early relapse in patients with RRMM. Isa-Kd showed better PFS, OS, and fewer TEAEs compared to Dara-Rd. These results suggest that Isa-Kd could be an effective treatment option for early relapse in non-lenalidomide refractory patients.
Article
Hematology
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, Kosei Matsue, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Takahiro Maeda, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, Shinsuke Iida
Summary: This study investigated the effectiveness and safety of Ixazomib plus Lenalidomide and Dexamethasone (IRd) in real-world clinical practice for 295 patients with relapsed/refractory multiple myeloma (RRMM) in Japan. The results showed that IRd regimen was effective and well-tolerated, providing a viable treatment option for RRMM patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki, Hiroshi Handa, Takaaki Chou, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, Kenshi Suzuki
Summary: This study evaluated the efficacy and safety of the oral proteasome inhibitor ixazomib plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. The results showed a 12-month event-free survival rate of 49% and a 12-month progression-free survival rate of 74%. The overall response rate was 73%, with frequent grade ≥3 adverse events being decreased neutrophil and platelet counts.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar, Roman Hajek
Summary: The study compared the efficacy of IRD and RD treatments in patients with multiple myeloma. Results showed that IRD performed better in terms of PFS and OS, especially in specific patient subgroups. Despite not being suitable for certain patients, IRD was found to be a more effective treatment option overall.
Article
Oncology
Elisabetta Antonioli, Sofia Pilerci, Irene Attucci, Gabriele Buda, Alessandro Gozzetti, Veronica Candi, Federico Simonetti, Maria Livia Del Giudice, Sara Ciofini, Michela Staderini, Sara Grammatico, Alessandra Buzzichelli, Maria Messeri, Monica Bocchia, Sara Galimberti, Alessandro. M. M. Vannucchi
Summary: This multicenter prospective observational study evaluated the efficacy of KRd combination therapy for multiple myeloma. The results showed an overall response rate of 95% and a median progression-free survival of 36 months. Patients who underwent autologous stem cell transplantation and achieved at least very good partial remission had longer progression-free survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Roman Hajek, Jiri Minarik, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G. Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A. Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L. Costello, Faith E. Davies, Vania T. M. Hungria, Hans C. Lee, Xavier Leleu, Noemi Puig, Robert M. Rifkin, Evangelos Terpos, Saad Z. Usmani, Katja C. Weisel, Jeffrey A. Zonder, Magda Barinova, Matyas Kuhn, Jiri Silar, Lenka Capkova, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren, Vladimir Maisnar
Summary: The study assessed the effectiveness and safety of using Ixazomib-Lenalidomide-Dexamethasone (IRd) in relapsed/refractory multiple myeloma patients, finding comparable results in routine clinical practice to those seen in clinical trials.
Article
Oncology
Paul G. Richardson, Albert Oriol, Alessandra Larocca, Joan Blade, Michele Cavo, Paula Rodriguez-Otero, Xavier Leleu, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrian Alegre, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Jan S. Moreb, Kenneth C. Anderson, Jacob P. Laubach, Sara Thuresson, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A. Bakker, Maria-Victoria Mateos
Summary: The combination of Melphalan flufenamide (melflufen) and dexamethasone showed significant efficacy and manageable safety profile in patients with heavily pretreated relapsed and refractory multiple myeloma (RRMM), including those with triple-class-refractory disease and extramedullary disease.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Darren Pan, Jonathan L. Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Robert F. Cornell, Jeffrey A. Zonder, Joseph W. Fay, Manuel R. Modiano, Erin L. Moshier, Selena A. Rush, Brian J. Tunquist, Ajai Chari
Summary: Filanesib demonstrates safety and promising activity in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma. Patients with 1q21 gain and t(11;14) show particularly encouraging progression-free survival rates.
Article
Oncology
Evangelos Terpos, Renato Zambello, Xavier Leleu, Thomas Kuehr, Sorina N. Badelita, Eirini Katodritou, Alessandra Brescianini, Tony Liang, Sally Wetten, Jo Caers
Summary: This study examined the real-world use of carfilzomib in patients with relapsed/refractory multiple myeloma and found that it was effective and had an acceptable safety profile in clinical practice.
Article
Hematology
Kevin R. Kelly, Sikander Ailawadhi, David S. Siegel, Leonard T. Heffner, George Somlo, Sundar Jagannath, Todd M. Zimmerman, Nikhil C. Munshi, Sumit Madan, Asher Chanan-Khan, Sagar Lonial, Suraj Chandwani, Ashot Minasyan, Markus Ruehle, Farima Barmaki-Rad, Afsaneh Abdolzade-Bavil, Faiza Rharbaoui, Eva Herrmann-Keiner, Thomas Haeder, Andrea Wartenberg-Demand, Kenneth C. Anderson
Summary: The study aimed to evaluate the safety and activity of indatuximab ravtansine in combination with immunomodulatory drugs in patients with relapsed or refractory multiple myeloma. The results showed that this combination therapy demonstrated good tolerability and antitumor activity in the patient population.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Tomas Jelinek, Alexandra Jungova, Petr Pavlicek, Lenka Pospisilova, Frantisek Sedlak, Jan Straub, Tomas Pika, Zdenka Knechtova, Anna Fidrichova, Ivanna Boichuk, Sabina Sevcikova, Vladimir Maisnar, Roman Hajek, Ludek Pour
Summary: We conducted a real-world evidence (RWE) analysis comparing the treatment of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) to lenalidomide and dexamethasone (Rd) in relapsed/refractory multiple myeloma patients (RRMM). Our analysis included 240 RRMM patients treated with Dara-Rd and 531 RRMM patients treated with Rd as a reference. The results showed that Dara-Rd achieved a significantly higher partial response or better response rate (91.2% vs. 69.9%) and longer median progression-free survival (26.9 months vs. 12.8 months) compared to Rd. In heavily pretreated RRMM patients, the efficacy of Dara-Rd treatment was limited, with the best outcomes observed in minimally pretreated patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Luciano J. Costa, Faith E. Davies, Gregory P. Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan-Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah A. Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji K. Kumar, Edward A. Stadtmauer
Summary: The study found that treatment with VenKd showed promising response rates in RRMM patients, with an overall response rate of 80% and 92% in t(11;14) patients. The median progression-free survival was 22.8 months.
